Trials / Completed
CompletedNCT06818656
The Unhide™ Project: Economic Impact Study of IVIG Treatment for PANS
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 65 (actual)
- Sponsor
- Brain Inflammation Collaborative · Academic / Other
- Sex
- All
- Age
- 2 Years – 89 Years
- Healthy volunteers
- Not accepted
Summary
The Economic Impact Study of IVIG treatment for PANS is a part of the Unhide™ Project, which is a research initiative developed by the Brain Inflammation Collaborative. Specifically, the Unhide™ project is a collection of investigations with the overall goal of better understanding the problems with thinking and mood that can sometimes be symptoms of conditions like autoimmune disease, infection-associated chronic conditions like Long COVID, ME/CFS, PANDAS, PANS, and other illnesses. Your contribution to this research will allow us to better describe these symptoms and understand what causes them, how they develop, and how they can best be treated and prevented. This study seeks to assess how PANDAS/PANS affects the financial well-being of families who pursue IVIG treatment, as well as the overall health and quality of life of children with the condition. By gathering data through this survey, we aim to gain important insights into the economic consequences of treating - or not treating - PANS with IVIG, including how it impacts parents' ability to work and children's ability to attend school. Key Eligibility Criteria * Aged 2-89, U.S. resident, fluent in English, and have access to computer and/or smartphone * Suspected or confirmed diagnosis of PANS/PANDAS * Have received IVIG OR have sought and/or been prescribed IVIG but have not received it
Conditions
- PANDAS
- PANS
- PANS Pediatric Acute-Onset Neuropsychiatric Syndrome
- Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
- Pediatric Acute-Onset Neuropsychiatric Syndrome
- Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections
Timeline
- Start date
- 2025-03-01
- Primary completion
- 2025-06-19
- Completion
- 2025-06-19
- First posted
- 2025-02-10
- Last updated
- 2025-09-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06818656. Inclusion in this directory is not an endorsement.